Express Pharma

Akums gets DCGI approval to launch Lobeglitazone for diabetes treatment in India

It offers a number of advantages including a higher safety profile, higher effectiveness in lower dosage, lower risk of hypoglycemia, and improved pancreatic beta-cell function

1 774